← Leaderboards
Jinjun Shi
Boston Children'S Hospital
$13,516,816
Attributed
$18,765,427
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,765,427 · 9
By mechanism
R01$16,719,229 · 6
R33$1,056,554 · 1
R00$724,224 · 1
K99$265,420 · 1
Top collaborators
- Hong Chen9 shared
- John Y-J Shyy4 shared
- Sanjay Srivastava4 shared
- Ira A Tabas2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Hong Chen$23,928,447
- Sanjay Srivastava$27,960,573
- John Y-J Shyy$24,226,917
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingNanoparticleGenerationsLipidsIn VitroTechnologyCessation Of LifeSmall Interfering RnaSurfaceIn VivoCellsMolecularUptakeNanotechnologyUnited StatesEngineeringFormulationChargeMessenger RnaPolymersPharmaceutical PreparationsProteinsPathway InteractionsBase
Grant awards (32)
A New-Generation Lipid-Lowering and Anti-Inflammatory siRNA Therapy for Atherosclerosis$787,453
R01 · FY2025 · HL · contact PI
The Role of Adaptor Protein Disabled-2 in Maintaining Endothelial Cell Function in Atherosclerosis$734,885
R01 · FY2025 · HL
Systemic RNA Delivery to Tumors$546,127
R01 · FY2025 · CA · contact PI
The role of signaling adaptor protein epsin in atherosclerosis$770,203
R01 · FY2024 · HL
The Role of Adaptor Protein Disabled-2 in Maintaining Endothelial Cell Function in Atherosclerosis$722,635
R01 · FY2024 · HL
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance$664,531
R01 · FY2024 · HL · contact PI
Systemic RNA Delivery to Tumors$518,820
R01 · FY2024 · CA · contact PI
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy$513,877
R33 · FY2024 · HL · contact PI
The role of signaling adaptor protein epsin in atherosclerosis$785,922
R01 · FY2023 · HL
The Role of Adaptor Protein Disabled-2 in Maintaining Endothelial Cell Function in Atherosclerosis$769,426
R01 · FY2023 · HL
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance$682,727
R01 · FY2023 · HL · contact PI
Systemic RNA Delivery to Tumors$546,127
R01 · FY2023 · CA · contact PI
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy$542,677
R33 · FY2023 · HL · contact PI
The Role of Adaptor Protein Disabled-2 in Maintaining Endothelial Cell Function in Atherosclerosis$812,576
R01 · FY2022 · HL
The role of signaling adaptor protein epsin in atherosclerosis$785,718
R01 · FY2022 · HL
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance$687,224
R01 · FY2022 · HL · contact PI
Systemic RNA Delivery to Tumors$535,205
R01 · FY2022 · CA · contact PI
The role of signaling adaptor protein epsin in atherosclerosis$796,770
R01 · FY2021 · HL
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance$711,340
R01 · FY2021 · HL · contact PI
Systemic RNA Delivery to Tumors$585,626
R01 · FY2021 · CA · contact PI
Systemic RNA Delivery to Tumors$540,226
R01 · FY2020 · CA · contact PI
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of Biologics$733,763
R01 · FY2019 · HL
Systemic RNA Delivery to Tumors$526,391
R01 · FY2019 · CA · contact PI
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of Biologics$738,492
R01 · FY2018 · HL
Systemic RNA Delivery to Tumors$545,070
R01 · FY2018 · CA · contact PI
Systemic RNA Delivery to Tumors$547,422
R01 · FY2017 · CA · contact PI
Systemic RNA Delivery to Tumors$644,550
R01 · FY2016 · CA · contact PI
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers$248,814
R00 · FY2015 · CA · contact PI
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers$241,349
R00 · FY2014 · CA · contact PI
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers$234,061
R00 · FY2013 · CA · contact PI
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers$132,710
K99 · FY2012 · CA · contact PI
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers$132,710
K99 · FY2011 · CA · contact PI